Literature DB >> 19814998

Measuring levels of proteins by various technologies: can we learn more by measuring turnover?

Michael J Kuhar1.   

Abstract

In routine experiments, scientists measure the levels of various substances such as proteins after various treatments. Detection of a change in levels suggests an impact of treatment on that particular protein. However, we sometimes forget the importance of turnover in this process. Proteins have half-lives that may change in response to treatments (which is in fact why levels may change), and an examination of half-lives may yield better clues as to how treatment affects the protein. After an exploration of the quantitative aspects of protein turnover, several interesting conclusions may be drawn. (1) Even though levels of some proteins may NOT change after treatments, their half-lives and turnovers do change, and these may be more sensitive indicators of the impact of treatments on the proteins of interest. (2) Treatments can affect protein levels because they alter either the synthesis or degradation of the protein or both. But, the rate of change of the levels depends on the half-life of the protein. If the experimenter waits only a fraction of a half-life of the protein after treatment, no significant change in level may be found since it can take up to 5 half-lives for the protein level to adjust to about 97% of its new level after treatment. (3) Half-lives of the same protein can vary in different species and experimental conditions may have to be altered if using different species. These factors suggest that a consideration of protein turnover and half-lives will be useful for future studies of this type. 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19814998      PMCID: PMC2812658          DOI: 10.1016/j.bcp.2009.09.029

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  18 in total

1.  Mesolimbic gender differences in peptide CART mRNA expression: effects of cocaine.

Authors:  P Fagergren; Y L Hurd
Journal:  Neuroreport       Date:  1999-11-08       Impact factor: 1.837

Review 2.  Chemokine and chemoattractant receptor expression: post-transcriptional regulation.

Authors:  Thomas A Hamilton; Michael Novotny; Shyamasree Datta; Palash Mandal; Justin Hartupee; Julie Tebo; Xiaoxia Li
Journal:  J Leukoc Biol       Date:  2007-04-04       Impact factor: 4.962

3.  Dopamine D1 and D2 receptors influence dopamine transporter synthesis and degradation in the rat.

Authors:  H L Kimmel; A R Joyce; F I Carroll; M J Kuhar
Journal:  J Pharmacol Exp Ther       Date:  2001-07       Impact factor: 4.030

4.  PCR differential display identifies a rat brain mRNA that is transcriptionally regulated by cocaine and amphetamine.

Authors:  J Douglass; A A McKinzie; P Couceyro
Journal:  J Neurosci       Date:  1995-03       Impact factor: 6.167

5.  Reinsertion or degradation of AMPA receptors determined by activity-dependent endocytic sorting.

Authors:  M D Ehlers
Journal:  Neuron       Date:  2000-11       Impact factor: 17.173

6.  The effects of cocaine on CART expression in the rat nucleus accumbens: a possible role for corticosterone.

Authors:  Richard G Hunter; Aleksandra Vicentic; George Rogge; Michael J Kuhar
Journal:  Eur J Pharmacol       Date:  2005-07-04       Impact factor: 4.432

7.  Cocaine-induced expression of the tetraspanin CD81 and its relation to hypothalamic function.

Authors:  M S Brenz Verca; D A Widmer; G C Wagner; J Dreyer
Journal:  Mol Cell Neurosci       Date:  2001-02       Impact factor: 4.314

Review 8.  The proteostasis boundary in misfolding diseases of membrane traffic.

Authors:  Darren M Hutt; Evan T Powers; William E Balch
Journal:  FEBS Lett       Date:  2009-08-20       Impact factor: 4.124

9.  Cocaine administration increases the fraction of CART cells in the rat nucleus accumbens that co-immunostain for c-Fos.

Authors:  G W Hubert; M J Kuhar
Journal:  Neuropeptides       Date:  2008-03-07       Impact factor: 3.286

10.  Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc/Arg3.1 essential for mGluR-LTD.

Authors:  Sungjin Park; Joo Min Park; Sangmok Kim; Jin-Ah Kim; Jason D Shepherd; Constance L Smith-Hicks; Shoaib Chowdhury; Walter Kaufmann; Dietmar Kuhl; Alexey G Ryazanov; Richard L Huganir; David J Linden; Paul F Worley
Journal:  Neuron       Date:  2008-07-10       Impact factor: 17.173

View more
  1 in total

1.  CART Peptides and Drugs of Abuse: A Review of Recent Progress.

Authors:  Michael J Kuhar
Journal:  J Drug Alcohol Res       Date:  2016-06-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.